Search

BACKGROUND: The pulmonary changes in COVID-19 are associated with cytokine release syndrome that could be treated with JAK inhibitors through the blockade of type I interferon and IL-6, IL-1, TNF and GM-CSF. CLINICAL CASE: A 32-year-old female with previous iron-deficiency anemia. She presented cough, tachypnea, fever, diarrhea and low oxygen saturation to 86% by pulse oximeter. PCR for SARS-CoV-2 was reported positive and bilateral pneumonia was seen on CT-scan. Diagnosis of COVID-19 pneumonia was confirmed. At diagnosis with erythrocyte sedimentation rate (ESR) 33 mm/hour, CRP 8.4 mg/dL, LDH 317 U/L, DD 412 ng/mL, lymphocytes 0.8 x 10³/μL, hemoglobin 7.4 g/dL with rest of bloodcount being normal. Ruxolitinib at 5 mg BID for 14 days was given. The patient was discharged after 7 days of hospital-length without supplemental oxygen and improvement in CT-scan and proinflammatory values: ESR 18 mm/hour, CPR 0.7 mg/mL, LDH 187 U/L, DD 308 ng/dL, lymphocytes 1.8 x 103/μL, hemoglobin 11.4 g/dL. CONCLUSIONS: Ruxolitinib proved to be a safe and efficient treatment for SARS-CoV-2 pneumonia with limitation of the cytokine release syndrome demonstrated by clinical evolution and proinflammatory markers. [ABSTRACT FROM AUTHOR]